|
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC’s announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at $2.2 billion, with shareholders to receive $58 per share. RTW says the price represents a 65% premium to RAPT’s closing price on Monday. RTW Investments Chief Investment Officer Rod Wong comments: ‘We are pleased to see GSK recognise the innovative work being done at RAPT, the potential of ozureprubart, and the promise it holds for patients living with severe food allergies. This is the second acquisition from the company’s portfolio so far in 2026, following Boston Scientific’s acquisition of Penumbra last week. We think that 2026 will be a stand-out year for biotech M&A as policy risks recede and large pharmas seek to replenish their pipelines in the face of a cumulative $170 billion patent cliff looming by 2032.’ Current stock price: $2.19, up 1.2% on Wednesday in London 12-month change: up 59% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
